Merijn Kant

Merijn Kant

Auto-generated profile, based on publicly available information

Merijn Kant

Department of Intensive Care, Amphia Hospital, 4818 CK Breda, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2019 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
SSSusanne Stads
Susanne Stads
KKK. Merijn Kant
K. Merijn Kant
MJMargriet Fleur Charlotte De Jong
Margriet Fleur Charlotte De Jong
WRWouter de Ruijter
Wouter de Ruijter
CCChrista M. Cobbaert
Christa M. Cobbaert
HSHeleen M Oudemans-van Straaten
Heleen M Oudemans-van Straaten
Prediction of successful discontinuation of continuous renal replacement therapy (CRRT) might reduce complications of over- and under-treatment. The aim of this study was to identify renal and non-renal predictors of short-term successful discontinuation of CRRT in patients in whom CRRT was stopped because renal recovery was expected and who were still in the Intensive Care Unit (ICU) at day 2 after stop CRRT. Prospective multicentre observational study in 92 patients alive after discontinuation of CRRT for acute kidney injury (AKI), still in the ICU and free from renal replacement therapy (RRT) at day 2 after discontinuation. Successful discontinuation was defined as alive and free from RRT at day 7 after stop CRRT. Urinary neutrophil gelatinase-associated lipocalin (NGAL) and clinical variables were collected. Logistic regression and Receiver Operator Characteristic (ROC) curve analysis were performed to determine the best predictive and discriminative variables. Discontinuation of CRRT was successful in 61/92 patients (66%). Patients with successful discontinuation of CRRT had higher day 2 urine output, better renal function indicated by higher creatinine clearance (6-h) or lower creatinine ratio (day 2/day 0), less often vasopressors, lower urinary NGAL, shorter duration of CRRT and lower cumulative fluid balance (day 0–2). In multivariate analysis renal function determined by creatinine clearance (Odds Ratio (OR) 1.066, 95% confidence interval (CI) 1.022–1.111, p = 0.003) or by creatinine ratio (day 2/day 0) (OR 0.149, 95% CI 0.037–0.583, p = 0.006) and non-renal sequential organ failure assessment (SOFA) score (OR 0.822, 95% CI 0.678–0.996, p = 0.045) were independently associated with successful discontinuation of CRRT. The area under the curve of creatinine clearance to predict successful discontinuation was 0.791, optimal cut-off of 11 ml/min (95% CI 6–16 ml/min) and of creatinine ratio 0.819 (95% CI 0.732–0.907) optimal cut-off of 1.41 (95% CI 1.27–1.59). In this prospective multicentre study we found higher creatinine clearance or lower creatinine ratio as best predictors of short-term successful discontinuation of CRRT, with a creatinine ratio of 1.41 (95% CI 1.27–1.59) as optimal cut-off. This study provides a practical bedside tool for clinical decision making.

19 January 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
RBRobbert Bentvelsen
Robbert Bentvelsen
AAAndreas L. E. Van Arkel
Andreas L. E. Van Arkel
TRTom A. Rijpstra
Tom A. Rijpstra
MKMerijn K. M. Kant
Merijn K. M. Kant
SBSimone Van Der Sar-Van Der Brugge
Simone Van Der Sar-Van Der Brugge
PVPaul Verweij
Paul Verweij
Background: Critically ill COVID-19 patients have proven to be at risk for developing invasive fungal infections. However, the incidence and impact of possible/probable COVID-19-associated pulmonary aspergillosis (CAPA) in severe COVID-19 patients varies between cohorts. We aimed to assess the incidence, risk factors, and clinical outcome of invasive pulmonary aspergillosis in a regional cohort of COVID-19 intensive care patients. Methods: We performed a regional, multicentre, retrospective cohort study in the intensive care units (ICUs) in North Brabant, The Netherlands. We included adult patients with rt-PCR-confirmed SARS-CoV-2 infection (COVID-19), requiring mechanical ventilation for acute respiratory distress syndrome. Demographics, clinical course, biomarker value, and treatment outcomes were compared between the groups with possible/probable CAPA from the main study centre and the regional centres, and without signs of CAPA from the main study centre as controls. The primary aim was to assess the regional impact of possible/probable CAPA in COVID-19 ICU patients, measured as all-cause mortality at 30 days after ICU admission. Secondary outcomes were risk factors for developing CAPA, based on underlying host factors and to identify the value of the mycological arguments for the diagnosing of CAPA. Results: Between 1 March and 30 April 2020, we included 123 patients with severe COVID-19: 29 patients (30.9%) in the main ICU with possible/probable CAPA, and 65 (69.1%) with no signs of CAPA; 29 patients in the regional ICUs with signs of CAPA. Patients’ characteristics and risk factors did not differ for CAPA and non-CAPA patients. Patients with COPD and/or chronic steroid medication developed CAPA more frequently, although this was not statistically significant. CAPA patients were admitted to the ICU earlier, had lower PF-ratios, and more often required renal replacement therapy. All-cause 30-day mortality was significantly higher in mechanically ventilated COVID-19 patients with possible/probable CAPA 39.7% (23/58) compared to patients without evidence for CAPA 16.9% (11/65) (OR 3.2 [95% CI 1.4–7.4] p = 0.005). Conclusion: The high incidence of possible and probable CAPA in critically ill COVID-19 patients is alarming. The increase in 30-day mortality in CAPA highlights the need for active surveillance and management strategies in critically ill COVID-19 patients.

8 August 2025 in Thrombosis Research
Verified
Journal Article
Open access
WSW.J.E. Stenger
W.J.E. Stenger
CUCorstiaan Den Uil
Corstiaan Den Uil
WRW.J.R. Rietdijk
W.J.R. Rietdijk
IAI. Al Amri
I. Al Amri
JMJose Montero-Cabezas
Jose Montero-Cabezas
JJJ. Jongkind
J. Jongkind
Catheter-directed thrombectomy (CDT) is a promising alternative to full dose thrombolysis in patients with acute high-risk pulmonary embolism (PE), expected to have a more direct effect on pulmonary artery clot burden and a better safety profile. Randomized trials evaluating the safety and efficacy of CDT in high-risk patients are currently unavailable. The TORPEDO-NL study is an investigator-initiated, publicly-funded, multicenter, open-label randomized controlled trial designed to evaluate the superiority of CDT over systemic thrombolysis in patients with high-risk PE. Adults with: 1) confirmed acute PE, 2) a high risk for mortality, and 3) CDT available and technically feasible, will be randomized 2:1 to CDT versus systemic thrombolysis. The primary outcome is the composite incidence of all-cause mortality, treatment failure, major bleeding, and all-cause stroke at day 30. Secondary outcomes include desirability of outcome ranking (DOOR) at day 7, length of hospital stay, patient-reported outcomes including quality of life and symptom burden, functional recovery, and 1-year cost-effectiveness. The trial anticipates recruiting 111 patients and is funded by the The Netherlands Health Care Institute, The Netherlands Organization for Health Research and Development, the Dutch Heart Foundation, and unrestricted grants from Penumbra Inc. and Inari Medical. gov number, NCT06833827. TORPEDO-NL is the first publicly-funded randomized trial to investigate the effect of CDT treatment specifically in high-risk PE patients. The trial is anticipated to play an important role in revising recommendations for high-risk PE treatment in international guidelines.

2 June 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
KDKatrijn Daenen
Katrijn Daenen
JHJilske A Huijben
Jilske A Huijben
ABAnders Boyd
Anders Boyd
LBLieuwe Bos
Lieuwe Bos
SSSara C M Stoof
Sara C M Stoof
PGPRoVENT- and PRoAcT-COVID Collaborative Group
PRoVENT- and PRoAcT-COVID Collaborative Group
Background: In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19. Objective: Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19. Methods: This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand. Results: As of April 2023, data have been collected for a total of 1500 patients, with data collection anticipated to be completed by December 2023. We expect the first results to be available in early 2024. Conclusions: This study protocol presents a strategy to investigate the effect of high-dose corticosteroids throughout the entire clinical course of hospitalized patients with COVID-19, from hospital admission to the ward or intensive care unit until hospital discharge. Moreover, our exploration of biomarker and gene expression profiles for targeted corticosteroid therapy represents a first step towards personalized COVID-19 corticosteroid treatment. Trial Registration: ClinicalTrials.gov NCT05403359; https://clinicaltrials.gov/ct2/show/NCT05403359 International Registered Report Identifier (IRRID): DERR1-10.2196/48183

1 November 2025 in Viruses
Verified
Journal Article
Open access
PDF file
SBSjoerd van der Bie
Sjoerd van der Bie
JAJohannes P. C. van Den Akker
Johannes P. C. van Den Akker
RFRamon Fluit
Ramon Fluit
SLSteven van Lelyveld
Steven van Lelyveld
MNMaarten E. Nuver
Maarten E. Nuver
MGMarco Goeijenbier
Marco Goeijenbier
Background: Influenza can cause severe complications, especially in patients with specific risk factors or comorbidities associated with poor outcomes. Some patients are at increased risk of a complicated disease course, including secondary infections, ICU admission, and the need for mechanical ventilation. The first post–COVID-19 seasonal influenza season placed a substantial burden on Dutch ICUs. This study investigates the disease course and outcomes of ICU patients with influenza. Methods: A retrospective influenza registry study was conducted across 34 Dutch ICUs, including patients aged 18 and older admitted to the ICU with a positive influenza RT-PCR test, between 1 November 2023 and 17 March 2024. Data on demographic information, medical history, clinical symptoms, laboratory and imaging results, parameters of mechanical ventilation, additional treatments, length of hospital stay, and mortality was retrieved from the electronic patient record. Results: A total of 498 patients were included in the study. The median age was 64 (IQR: 55–72) years and 58.8% of the patients were men. The most common comorbidities were cardiovascular disease (34.1%), chronic obstructive pulmonary disease (COPD) (31.5%), and diabetes (22.3%). Bacterial co-infections were present in 37.6% of the patients. Invasive mechanical ventilation (IMV) was necessary in 46.0% of patients, 38.0% of those requiring IMV were treated in prone position. A substantial mortality rate was observed, with an ICU mortality rate of 21.9% and an additional hospital mortality rate of 5.2%. Conclusion: This study described the characteristics and course of disease of all patients with laboratory-confirmed influenza infection admitted to one of the 34 participating Dutch ICUs between November 2023 and March 2024. The major findings of this study are the substantial mortality rate, a high proportion of patients with bacterial co-infections, and a significant percentage of patients requiring IMV and prone position ventilation. Finally, patients without comorbidities that were admitted to the ICU with an influenza virus infection showed severe disease parameters but had a lower mortality than patients with comorbidities.

19 December 2020 in medRxiv
Verified
Preprint
Open access
PDF file
D(Dutch Covid & Thrombosis Coalition (Dctc)
Dutch Covid & Thrombosis Coalition (Dctc)
MHMenno V Huisman
Menno V Huisman
MSMilou Am Stals
Milou Am Stals
MGMarco Jjh Grootenboers
Marco Jjh Grootenboers
CGCoen van Guldener
Coen van Guldener
FKFrederikus A. Klok
Frederikus A. Klok
Background: Whereas accumulating studies on COVID-19 patients report high incidences of thrombotic complications, large studies on clinically relevant thrombosis in patients with other respiratory tract infections are lacking. How this high risk in COVID-19 patients compares to those observed in hospitalized patients with other viral pneumonias such as influenza is unknown. Objectives: To assess the incidence of venous and arterial thrombotic complications in hospitalized influenza patients as opposed to that observed in hospitalized COVID-19 patients. Methods: Retrospective cohort study; we used data from Statistics Netherlands (study period: 2018) on thrombotic complications in hospitalized influenza patients. In parallel, we assessed the cumulative incidence of thrombotic complications – adjusted for competing risk of death - in patients with COVID-19 in three Dutch hospitals (February 24th - April 26th 2020). Results: Of the 13.217 hospitalized influenza patients, 437 (3.3%) were diagnosed with thrombotic complications, versus 66 (11%) of the 579 hospitalized COVID-19 patients. The 30-day cumulative incidence of any thrombotic complication in influenza was 11% (95%CI 9.4-12) versus 25% (95%CI 18-32) in COVID-19. For venous thrombotic complications (VTE) and arterial thrombotic complications alone, these numbers were respectively 3.6% (95%CI 2.7-4.6) and 7.5% (95%CI 6.3-8.8) in influenza versus 23% (95%CI 16-29) and 4.4% (95%CI 1.9-8.8) in COVID-19. Conclusions: The incidence of thrombotic complications in hospitalized influenza patients was lower than in hospitalized COVID-19 patients. This difference was mainly driven by a high risk of VTE complications in the COVID-19 patients admitted to ICU. Remarkably, influenza patients were more often diagnosed with arterial thrombotic complications. Essentials: It is unknown how COVID-19 compares to patients with other virus infections regarding thrombosis. Hospitalized patients with influenza and COVID-19 were evaluated and compared to each other. 30-day cumulative incidence of thrombosis was lower in influenza (11%) than in COVID-19 (25%). Difference was mainly driven by a high risk of VTE in COVID-19 patients admitted to the ICU.